XENE Q3 2017 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$264,000-36.1% YoY

Gross Profit

-$7M-2613.6% margin

Operating Income

-$9M-3274.2% margin

Net Income

-$8M-2932.6% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+1660.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$567,000

Balance Sheet

Total Assets

$46M

Total Liabilities

$3M

Stockholders' Equity

$43M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$264,000	$413,000	-36.1%
Gross Profit	-$7M	-$78,000	-8746.2%
Operating Income	-$9M	-$7M	-17.9%
Net Income	-$8M	-$8M	-0.4%